We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• May 2021

This study thus identified a novel small molecule that rapidly kills MLL-rearranged leukemia cells by targeting a metabolic vulnerability ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• May 2019

The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• January 2022

Epidermal growth factor receptor (EGFR) is over-expressed in many brain tumors. This paper examines mutations the EGFR that make the cell it is produced in... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• April 2014

Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• October 2021

Consideration of the future for asbestos-related lung disease includes screening those at highest risk ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• March 2019

Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response.  ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2024
• April 2024

We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681) on the association between behavioral risk factors... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• December 2012

Timo W. Joost Lassmann Lesterhuis T WJL BSc (Hons) MSc PhD Feilman Fellow; Program Head, Precision Health and Team Lead, Computational Biology Program Head, Cancer; Chronic and Severe Diseases RFA Deputy Head timo.lassmann@telethonkids.org.au ...

• 1. Telethon Kids Institute
• Projects

We found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• June 2019

Medulloblastoma is curable in approximately 70 % of patients. Over the past decade, progress in improving survival using conventional therapies has stalled... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• November 2013

Cranial radiation therapy is essential in treating many pediatric cancers, especially brain tumors; however, its use comes with the risk of developing second malignancies. Cranial radiation-induced gliomas (RIGs) are aggressive high-grade tumors with a dismal prognosis, for which no standard therapy exists. A definitive molecular signature for RIGs has not yet been established. We sought to address this gap by performing a systematic review and meta-analysis of the molecular features of cranial RIGs. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• August 2021